Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Xortx Therapeutics Inc (XRTX.VN)

Xortx Therapeutics Inc (XRTX.VN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX Venture]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX Venture]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 9,727
  • Shares Outstanding, K 2,904
  • Annual Sales, $ 0 K
  • Annual Income, $ -2,158 K
  • 60-Month Beta 0.36
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.54
Trade XRTX.VN with:
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm -1.09
  • Most Recent Earnings $1.36 on N/A
  • Latest Earnings Date N/A
  • Annual Dividend & Yield N/A (N/A)
  • Most Recent Dividend N/A on N/A
  • Sectors:

    TSX Biotechnology

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.250 +3.08%
on 05/16/24
4.260 -21.36%
on 04/29/24
-0.950 (-22.09%)
since 04/17/24
3-Month
3.090 +8.41%
on 02/20/24
9.350 -64.17%
on 03/07/24
+0.250 (+8.06%)
since 02/16/24
52-Week
2.650 +26.42%
on 12/28/23
9.990 -66.47%
on 07/27/23
-5.110 (-60.40%)
since 05/17/23

Most Recent Stories

More News
Stocks in play: XORTX Therapeutics Inc.

Announces that it has received TSX Venture Exchange approval to amend the terms of the balance of outstanding ...

XRTX.VN : 3.350 (unch)
Stocks in play: XORTX Therapeutics Inc

Announced the grant of Orphan Drug Designation for oxypurinol – “orphan-drug designation request of ...

XRTX.VN : 3.350 (unch)
XORTX Announces Submission to European Medicines Agency

Scientific Advice from EMA Committee for Medicinal Products for Human Use Requested...

XRTX.VN : 3.350 (unch)
XRTX : 2.50 (+6.38%)
XORTX Announces Positive Topline Results from Pharmacokinetics Bridging Clinical Trial

Clinical Trial Shows Substantially Improved Bioavailiability...

XRTX.VN : 3.350 (unch)
XRTX : 2.50 (+6.38%)
XORTX Announces Pre-Phase 3 Meeting Request with US Food and Drug Administration (FDA)

CALGARY, Alberta, July 07, 2022 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a...

XRTX.VN : 3.350 (unch)
XRTX : 2.50 (+6.38%)
XORTX to Present at BIO International Convention 2022

CALGARY, Alberta, June 13, 2022 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a...

XRTX.VN : 3.350 (unch)
XRTX : 2.50 (+6.38%)
XORTX Welcomes New Member to the Board of Directors and Appoints Chair

CALGARY, Alberta, June 06, 2022 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a...

XRTX.VN : 3.350 (unch)
XRTX : 2.50 (+6.38%)
XORTX Receives Small and Medium Enterprise Status for the European Union

CALGARY, Alberta, April 20, 2022 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a...

XRTX.VN : 3.350 (unch)
XRTX : 2.50 (+6.38%)
XORTX Receives No Objection Letter from Health Canada

Bridging Pharmacokinetics Study Autosomal Dominant Polycystic Kidney Disease – XRx-008 Program...

XRTX.VN : 3.350 (unch)
XRTX : 2.50 (+6.38%)
XORTX Announces Grant of US Patent

Patent supporting Autosomal Dominant Polycystic Kidney Disease Granted – XRx-008 Program...

XRTX.VN : 3.350 (unch)
XRTX : 2.50 (+6.38%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

XORTX Therapeutics Inc is a clinical-stage biotechnology company focused on identifying, developing, and potentially commercializing therapies to treat progressive kidney disease modulated by aberrant purine and uric acid metabolism and uric acid metabolism in orphan (rare) disease indications such as...

See More

Key Turning Points

3rd Resistance Point 3.350
2nd Resistance Point 3.350
1st Resistance Point 3.350
Last Price 3.350
1st Support Level 3.350
2nd Support Level 3.350
3rd Support Level 3.350

See More

52-Week High 9.990
Fibonacci 61.8% 7.186
Fibonacci 50% 6.320
Fibonacci 38.2% 5.454
Last Price 3.350
52-Week Low 2.650

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar